



Lecture Code : JS08-S4

Session Name : Asian Pacific Nephrology Forum

Session Topic : Asian Pacific Nephrology Forum

Date & Time, Place : June 13 (Sat) / 08:30-10:10 / Room 4 (203), 2F

ANZDATA – Using Registry Data to Drive Change

Stephen McDonald

SAHMRI, Australia

ANZDATA – Using Registry Data to Drive Change ANZDATA is a clinical quality Registry including people receiving long term dialysis and kidney transplantation across Australia and New Zealand. It was established in 1977 from a merger of existing data sets, with coverage extending to first kidney transplantation and dialysis treatment in Australia in 1963. As a Clinical Quality Registry, core roles are to support health service planning, safety and quality, and clinical research. It produces a variety of output, including public- facing annual reports and special reports, various national and provider-level safety and quality reports and is extensively utilized for clinical research projects. The presentation will summarize the impact of ANZDATA across these 3 areas, including enablers and barriers. 1. Health service planning. In addition to routine reports of incidence and prevalence at national and state-level, we have utilised a Markov model approach to predict the demand for dialysis services. We have identified geographic areas of increased growth rates (“hot spots”) and surveys of availability of haemodialysis treatment. 2. Safety and Quality. Inherently, quality of care is about access to and outcomes of healthcare; Registries are well placed to describe and address these issues. Two examples of areas where ANZDATA has had an impact are peritoneal dialysis related peritonitis rates and access to kidney transplantation for Aboriginal and Torres Strait Islander people. 3. Research. Data from ANZDATA has been widely used. These include a variety of methodologies, including cohort studies and linkage with other datasets to address a variety of research questions. A particular example where ANZDATA has been able to have an impact is in the area of Registry based trials. The “BEST Fluids” was the first completed; a further 4 are underway. Both the impact of individual trials and Registry based trials as a methodology will be discussed.

Keywords: Registry, Dialysis, Transplantation, Epidemiology, Quality